A Phase I Trial of Regorafenib and Cetuximab in Patients With Advanced Malignancy

Trial Profile

A Phase I Trial of Regorafenib and Cetuximab in Patients With Advanced Malignancy

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Cetuximab (Primary) ; Regorafenib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 25 Jan 2016 Status changed from active, no longer recruiting to recruiting according to ClinicalTrials.gov.
    • 14 Jan 2016 Status changed from recruiting to active, no longer recruiting according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top